Current Tumor Cells News and Events

Current Tumor Cells News and Events, Tumor Cells News Articles.
Sort By: Most Relevant | Most Viewed
Page 1 of 25 | 1000 Results
Oncotarget: Improved therapeutic efficacy of unmodified anti-tumor antibodies
The Oncotarget findings suggest that MEKi induced an increased expression of tumor-associated antigens, which in combination with anti-tumor antibodies, generated a robust adaptive anti-tumor response that was sustained by immune checkpoint inhibition therapy. (2021-01-25)

Oncotarget: Drug-resistant cells grow exponentially in metastatic prostate cancer
The Oncotarget authors show that the drug-resistant, metastasis-causing cells are capable of producing drug-resistant, exponentially growing tumors, responsible for tumor growth as a patient receives different treatments (2021-01-25)

Oncotarget: Prognostic biomarker for patients with hepatocellular carcinoma
Reduced expression of TBX15 in tumor tissue represents a potential biomarker for predicting poor survival of patients with HCC (2021-01-25)

Aging-US: PAM (PIK3/AKT/mTOR) signaling in glia: potential contributions to brain tumors
'The consideration of aberrant PIK3/AKT/mTOR signaling in glia during aging elucidates several therapeutic opportunities for brain tumors'. (2021-01-25)

Fighting cancer from a chair
Cisplatin has been used to treat cancer since the 1970s. Since then, many other platinum-containing cytostatic drugs have been developed, such as triplatinNC, a highly charged complex that contains three ligand-bridged platinum atoms. Unlike cisplatin, this drug also directly inhibits metastasis. The reason for this seems to be modulation of the geometry of a sugar component of heparan sulfate, an important component of the extracellular matrix, reports a research team in the journal Angewandte Chemie. (2021-01-25)

Missing protein helps small cell lung cancer evade immune defenses
Small cell lung cancer (SCLC) cells are missing a surface protein that triggers an immune response, allowing them to hide from one of the body's key cancer defenses, a new study led by UT Southwestern researchers suggests. The findings, reported online today in Cancer Research, a journal of the American Association for Cancer Research, could lead to new treatments for SCLC, which has no effective therapies. (2021-01-25)

Bioorthogonally catalyzed lethality strategy generates targeting drugs within tumor
Selectively killing tumor while not causing damage to normal cells still remains a challenge in cancer chemotherapy. Professor Hongke Liu from Nanjing Normal University together with Professor Jing Zhao and Professor Zijian Guo from Nanjing University developed a novel strategy---bioorthogonally-catalyzed lethality to generate efficient anticancer species between two non-toxic components only within cancer cells and tumors without external catalysts, realizing the precise and efficient anticancer chemotherapy. (2021-01-25)

When -- not what -- obese mice ate reduced breast cancer risk
University of California San Diego School of Medicine and Moores Cancer Center researchers report that intermittent fasting reduced breast cancer risk in obese mice. (2021-01-25)

Immunology - Functionality of immune cells in early life
A study by Ludwig-Maximilians-Universitaet (LMU) in Munich researchers shows that putatively immature dendritic cells found in young children are able to induce robust immune responses. The results could lead to improved vaccination protocols. (2021-01-21)

Vaccine produces long-lasting anti-tumor response in patients with melanoma
Patients treated with a vaccine tailored to mutated proteins on patients' own tumor cells, continue to have a strong immune response to the cancer four years after being vaccinated. Results demonstrate the ability of personalized cancer vaccines to provide long-term immunity against some cancers. (2021-01-21)

Detailed tumour profiling
As part of a clinical study involving patients from the University Hospitals in Zurich and Basel, researchers are conducting a thorough and highly precise investigation into the molecular and functional properties of tumours. Their goal is to help physicians to better determine which treatment will best match every patient's cancer and thus be most effective. (2021-01-21)

Combining best of both worlds for cancer modeling
Treatment options for many types of cancers remain limited, due partly to the in vitro tools used to model cancers and that results from animal studies do not always translate well to human disease. These shortcomings point to a clear need for a better, patient-specific model. Researchers suggest bioengineered microscale organotypic models can address this need. They discuss the advantages and capabilities of this technique, as well as its challenges, in the journal APL Bioengineering. (2021-01-21)

Study finds racial disparities in breast cancer prognosis testing
Women with hormone-dependent breast cancer typically have a favorable prognosis, but new research has found that even after adjusting for age at diagnosis, tumor stage and treatment, there is still a significant mortality gap between Black and non-Hispanic white women with axillary node-negative, hormone-dependent tumors that have a comparable Oncotype Recurrence Score. (2021-01-21)

New combination of immunotherapies shows great promise for treating lung cancer
McMaster University researchers have established in lab settings that a novel combination of two forms of immunotherapy can be highly effective for treating lung cancer, which causes more deaths than any other form of cancer. (2021-01-21)

Designer DNA therapeutic wipes out cancer stem cells, treats multiple myeloma in mice
UC San Diego study supports launch of Phase I clinical trial to test a designer DNA agent -- an antisense oligonucleotide that targets a gene called IRF4 -- in patients with multiple myeloma. (2021-01-20)

Scientists discover link between nicotine and breast cancer metastasis
Scientists at Wake Forest School of Medicine have found that nicotine promotes the spread of breast cancer cells into the lungs. (2021-01-20)

Reviving exhausted immune cells to fight cancer
Eliminating a single gene can turn exhausted cancer-fighting immune cells known as CD8+ T cells back into refreshed soldiers that can continue to battle malignant tumors, a new study led by UT Southwestern researchers suggests. The findings, published online this week in the Journal for Immunotherapy of Cancer, could offer a new way to harness the body's immune system to attack cancers. (2021-01-20)

Spontaneous cell fusions amplify genetic diversity within tumors, Moffitt researchers say
Scientists generally believe that cancers lack a powerful and important diversification mechanism available to pathogenic microbes - the ability to exchange and recombine genetic material between different cells. However, in a new article published in Nature Ecology & Evolution, Moffitt Cancer Center researchers demonstrate that this belief is wrong and that cancer cells are capable of exchanging and recombining their genetic material with each other through a mechanism mediated by cell fusions. (2021-01-20)

The physics behind tumor growth
Researchers at Duke University have developed a predictive theory for tumor growth that approaches the subject from a new point of view. Rather than focusing on the biological mechanisms of cellular growth, the researchers instead use thermodynamics and the physical space the tumor is expanding into to predict its evolution from a single cell to a complex cancerous mass. (2021-01-20)

New approach emerges to better classify, treat brain tumors
A look at RNA tells us what our genes are telling our cells to do, and scientists say looking directly at the RNA of brain tumor cells appears to provide objective, efficient evidence to better classify a tumor and the most effective treatments. (2021-01-19)

Moffitt researchers identify how cancer cells adapt to survive harsh tumor microenvironments
To better understand the conditions that select for the Warburg Effect and the mechanisms where cells can express this metabolic adaptation, Moffitt researchers subjected nonmalignant cells to the harsh tumor microenvironment that is present during early carcinogenesis, known as ductal carcinoma in situ. In a new research article published in the Proceedings of the National Academy of Sciences, the Moffitt team shows that these conditions select for cells to express a Warburg Effect. (2021-01-19)

New computational tool reliably differentiates between cancer and normal cells from single-cell RNA-sequencing data
MD Anderson researchers have developed a new computational tool to accurately differentiate between cancer cells and normal cells when analyzing large single-cell RNA-sequencing data. (2021-01-18)

A mathematical study describes how metastasis starts
A scientific study carried out by the Universidad Carlos III de Madrid (UC3M) and the Universidad Complutense de Madrid (UCM) has produced a mathematical description of the way in which a tumor invades the epithelial cells and automatically quantifies the progression of the tumor and the remaining cell islands after its progression. The model developed by these researchers could be used to better understand the biophysical characteristics of the cells involved when developing new treatments for wound healing, organ regeneration, or cancer progression. (2021-01-18)

A master cancer gene hijacks a 'molecular crowbar' to make breast cancer cells invasive
Researchers investigated how cancer genes lead to the breakdown of the capsule that prevents cancerous cells from invading the surrounding healthy tissues and - find a hijacked ''molecular crowbar''. The new findings help understand the mechanisms of cancer spreading and reveal a cancer vulnerability. (2021-01-18)

Novel organoid models: Illuminating path to cervical cancers
How do tumors develop in the cervix? Many new details are now known about this question. This is also thanks to Dr. Cindrilla Chumduri from the Biocentre at the University of Würzburg. (2021-01-18)

An unexpected, and novel, target for prostate cancer - our biological clock
Researchers find that CRY-1, a regulator of circadian rhythms, promotes tumor progression by altering DNA repair. (2021-01-15)

Chemotherapy with light; only one injection required
Researchers in South Korea have developed a phototherapy technology that can significantly increase efficiency while reducing the pain of chemotherapy and minimizing side effects after treatment. The research team has developed a cancer-targeted phototherapeutic agent that promises complete elimination of cancer cells without side effects. It involves only one injection and repeated phototherapy. (2021-01-14)

Researchers link cellular transport pathway to aggressive brain cancer
Researchers at McGill University have identified a new cellular pathway that limits the growth and spread of brain tumors by controlling the recycling of cell surface receptor proteins. The study, which will be published January 14 in the Journal of Cell Biology (JCB), suggests that the pathway, which involves a protein called Rab35, is defective in many patients with glioblastoma and that restoring Rab35's activity could be a new therapeutic strategy for this deadly form of brain cancer. (2021-01-14)

Triggering tumor antiviral immune response in triple negative breast cancer
Researchers at Baylor College of Medicine have discovered how therapeutics targeting RNA splicing can activate antiviral immune pathways in triple negative breast cancers (TNBC) to trigger tumor cell death and signal the body's immune response. (2021-01-14)

Bladder cancer -- When to use chemotherapy
In patients with bladder cancer, chemotherapy effectiveness is partially determined by the body's immune system response to the malignancy. This is the conclusion of research conducted by a team of scientists from Charité -- Universitätsmedizin Berlin and the Berlin Institute of Health. The findings, which have been published in Science Translational Medicine*, can be used to predict treatment success and may increase survival in patients with bladder cancer. (2021-01-14)

Study demonstrates efficacy of new treatment for neurofibromatosis type 1-related tumors
Based on preclinical studies of an investigational drug to treat peripheral nerve tumors, researchers at Children's Hospital of Philadelphia (CHOP) as part of the Neurofibromatosis Clinical Trials Consortium have shown that the drug, cabozantinib, reduces tumor volume and pain in patients with the genetic disorder neurofibromatosis type 1 (NF1). The results of the Phase 2 clinical trial, co-chaired by Michael J. Fisher, MD at CHOP, were published recently in Nature Medicine. (2021-01-14)

Cancer models created by mechanical engineers offer new insight into tumor growth
In research published today in Integrative Biology, a team of engineers from Rensselaer developed an in vitro -- in the lab -- lymphatic vessel model to study the growth of tumor emboli, collections of tumor cells within vessels that are often associated with increased metastasis and tumor recurrence. (2021-01-14)

The role of T cells in fighting cancer
Why do some hosts' immune systems reject tumors easily, while others have a harder time doing so? It depends on the types of the immune cells known as CD8 T cells and how a host's specific T cells match up with the neoantigens present in the tumor. (2021-01-14)

Ovarian cancer cells adapt to their surroundings to aid tumor growth
A description of how ovarian cancer cells adapt to survive and proliferate in the peritoneal cavity has been detailed by a new study. It shows structures inside the cells change as the disease progresses, to help the cells grow in an otherwise hostile environment of low oxygen and nutrients. Understanding how these cellular adaptations are regulated could herald new targeted treatment options against the fifth-leading cause of cancer-related deaths in women. (2021-01-13)

Scoring system to redefine how U.S. patients prioritized for liver transplant
Researchers with Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine are collaborating with faculty at the University of Pennsylvania to develop a risk score that more comprehensively prioritizes liver cancer patients for transplantation. (2021-01-13)

New humanized mouse model provides insight into immunotherapy resistance
Wistar scientists have created an advanced humanized immune system mouse model that allows them to examine resistance to immune checkpoint blockade therapies in melanoma. It has revealed a central role for mast cells. (2021-01-12)

Texas A&M research explores how melanoma grows and spreads
The first step in treating cancer is understanding how it starts, grows and spreads throughout the body. A relatively new cancer research approach is the study of metabolites, the products of different steps in cancer cell metabolism, and how those substances interact. (2021-01-12)

Scientists study use of abundant enzyme in tumor cells to monitor cancer treatment
After 14 years studying the action of the enzyme LMWPTP in tumor cells, Brazilian researchers conclude that the molecule is associated with chemotherapy resistance and metastasis. (2021-01-12)

Discovery of a new approach to inhibiting a highly treatment-refractory liver cancer
Blocking placental growth factor (PlGF), a member of the vascular endothelial growth factor family, inhibits the progression of intrahepatic cholangiocarcinoma (ICC) and enhances the efficacy of chemotherapy in mouse models. This novel approach to targeting the connective tissue microenvironment of ICC, a rare but notoriously treatment-resistant form of liver cancer, could pave the way for combination therapies, including chemotherapy and immune checkpoint blockade. (2021-01-12)

Killing cancer by unleashing the body's own immune system
The body's immune system is the first line of defense against infections like bacteria, viruses or cancers. Some cancers, however, have developed the art of molecular deception to avoid destruction by the body's immune system. Now, a University of Missouri researcher might have found a new way to help the body's immune system get past that deception and destroy the cancer. (2021-01-12)

Page 1 of 25 | 1000 Results
   First   Previous   Next      Last   
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.